+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07770685

Evaluation of ASP2767 Gene Therapy Safety and Vision Effects in Open-Angle Glaucoma Patients Using Randomized, Controlled Injections

Led by Astellas Pharma Global Development, Inc. · Updated on 2026-10-22

156

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Open-angle glaucoma is a common eye disease that damages the optic nerve and can lead to vision loss. Current treatments like eye drops, laser therapy, and surgery may not work for everyone, so researchers are exploring better options. This trial studies ASP2767, a gene therapy given by injection into the eye, aiming to protect nerve cells and potentially slow vision loss in people with glaucoma. The study has two phases. Phase 1 is an open-label dose-escalation phase where small groups receive increasing doses of ASP2767 along with medicines to reduce inflammation risk. Phase 2 is a randomized, double-masked phase where participants receive either a high dose, a low dose of ASP2767, or a sham injection, combined with either prophylactic medicine or placebo. Both phases involve a single injection into one eye. Participants will be followed for about one year after injection with scheduled clinic visits for health checks and vision testing. Assessments include eye exams, imaging, blood and urine samples, and monitoring for safety and visual function changes. The study aims to identify safe dosing and evaluate effects on vision while closely observing any side effects.

CONDITIONS

Brief Title

A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage

Research Team

A

Astellas Pharma Global Development Inc.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here